Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Analysis of PFS in CLL: Pts Who Received First-Line Bendamustine-Rituximab Depending on The Elimination Rate of The MRD and IGHV

0 views
March 30, 2020
Comments 0
Login to view comments. Click here to Login